Workflow
传染病类
icon
Search documents
奥泰生物收盘上涨1.46%,滚动市盈率18.71倍,总市值59.67亿元
Sou Hu Cai Jing· 2025-08-16 12:54
8月15日,奥泰生物今日收盘75.26元,上涨1.46%,滚动市盈率PE(当前股价与前四季度每股收益总和 的比值)达到18.71倍,总市值59.67亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)10奥泰生物18.7119.731.5159.67亿行业平均 56.5852.305.00119.53亿行业中值39.9739.072.9157.03亿1九安医疗11.3611.490.89191.70亿2英科医疗 15.6416.861.39247.04亿3山东药玻16.2816.331.87154.02亿4新华医疗16.6315.411.36106.59亿5奥美医疗 17.1216.781.7661.87亿6振德医疗17.3816.381.1163.10亿7九强生物17.7016.462.1787.65亿8康德莱 18.0418.051.4938.87亿9维力医疗18.5219.782.3343.40亿11鱼跃医疗20.2019.812.73357.68亿12安图生物 20.8619.922.68237.88亿 从行业市盈率排名来看,公司所处的医疗器械行业市盈率平均56.58倍,行业中值39.97倍 ...
奥泰生物收盘上涨1.73%,滚动市盈率18.57倍,总市值59.21亿元
Sou Hu Cai Jing· 2025-08-06 11:37
Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Aotai Biological Technology Co., Ltd, indicating a low PE ratio compared to industry averages [1][2] - As of August 6, Aotai's stock closed at 74.69 yuan, with a rolling PE ratio of 18.57, marking a new low in 85 days, and a total market capitalization of 5.921 billion yuan [1] - The average PE ratio for the medical device industry is 53.93, with a median of 37.81, positioning Aotai at 41st among its peers [1][2] Group 2 - For Q1 2025, Aotai reported revenue of 208 million yuan, a year-on-year increase of 4.28%, and a net profit of 61.216 million yuan, reflecting a 36.68% increase [2] - The company's gross profit margin stands at 55.63%, indicating strong profitability relative to its revenue [2] - Aotai's main business focuses on the research, production, and sales of in vitro rapid diagnostic reagents, with key products in infectious diseases, drug abuse, women's health, COVID-19 testing, tumors, and myocardium [1]
奥泰生物收盘上涨1.21%,滚动市盈率16.63倍,总市值53.04亿元
Sou Hu Cai Jing· 2025-07-11 12:32
Group 1 - The core viewpoint of the articles highlights the performance and valuation of Aotai Biological, a company in the medical device industry, which has a current market capitalization of 5.304 billion yuan and a rolling PE ratio of 16.63 times, significantly lower than the industry average of 52.06 times [1][2] - Aotai Biological's main business focuses on the research, production, and sales of in vitro rapid diagnostic reagents, with key products including infectious disease tests, drug abuse tests, women's health tests, COVID-19 tests, tumor tests, and myocardial tests [1] - As of March 31, 2025, Aotai Biological had 5,431 shareholders, an increase of 165 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1] Group 2 - In the first quarter of 2025, Aotai Biological reported revenue of 208 million yuan, representing a year-on-year increase of 4.28%, and a net profit of 61.2163 million yuan, reflecting a year-on-year growth of 36.68%, with a gross profit margin of 55.63% [2] - The company ranks 39th in terms of PE ratio within its industry, which has a median PE ratio of 37.22 times [1][2] - Aotai Biological has received several accolades, including being named one of the "Top 20 ESG Strategic Philanthropy Influencers" in Hangzhou and recognized as a "2024 A-share Listed Company Growth Power Annual Enterprise" [1]
奥泰生物收盘上涨1.70%,滚动市盈率16.19倍,总市值51.64亿元
Sou Hu Cai Jing· 2025-06-24 13:45
Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Aotai Biological Technology Co., Ltd., emphasizing its growth in revenue and net profit, as well as its competitive valuation in the medical device industry [1][2] Group 2 - As of the first quarter of 2025, the company reported a revenue of 208 million yuan, representing a year-on-year increase of 4.28%, and a net profit of 61.22 million yuan, reflecting a year-on-year growth of 36.68% [2] - The company's rolling price-to-earnings (PE) ratio stands at 16.19, significantly lower than the industry average of 49.12 and the industry median of 36.07, indicating a favorable valuation compared to peers [1][2] - Aotai Biological's total market capitalization is 5.164 billion yuan, with 30 institutions holding shares, including 24 funds, 5 other entities, and 1 social security fund, totaling 44.01 million shares valued at 3.224 billion yuan [1]
奥泰生物收盘上涨2.36%,滚动市盈率16.04倍,总市值51.14亿元
Sou Hu Cai Jing· 2025-05-29 12:29
Core Insights - The stock price of Aotai Bio closed at 64.51 yuan, up 2.36%, with a rolling PE ratio of 16.04, marking a new low in 13 days, and a total market capitalization of 5.114 billion yuan [1] - Aotai Bio ranks 39th in the medical device industry, which has an average PE ratio of 49.64 and a median of 36.36 [1] - As of the first quarter of 2025, 30 institutions hold shares in Aotai Bio, including 24 funds, with a total holding of 44.0114 million shares valued at 3.224 billion yuan [1] Company Overview - Aotai Bio specializes in the research, production, and sales of in vitro rapid diagnostic reagents, focusing on infectious diseases, drug abuse, women's health, COVID-19 testing, tumors, and myocardium [1] - The company has received several accolades, including being named one of the "Top 20 ESG Strategic Philanthropy Influencers" in Hangzhou in September 2024, and winning the "2024 China A-share Listed Company Growth Power Annual Award" in October 2024 [1] Financial Performance - In the first quarter of 2025, Aotai Bio reported revenue of 208 million yuan, a year-on-year increase of 4.28%, and a net profit of 61.2163 million yuan, up 36.68% year-on-year, with a gross profit margin of 55.63% [2] - The company's PE ratio (TTM) stands at 16.04, while the industry average is 49.64, indicating a significant valuation gap [2]